McDermott Will & Emery advised Egle Therapeutics SAS, while Morgan Lewis acted for Takeda on the deal.
Egle Therapeutics SAS closed a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). The alliance meets the key the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
Under the terms of the agreement, Egle Therapeutics SAS will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle Therapeutics will receive an upfront payment and research funding, and will be eligible to receive additional development and sales milestone payments based on the exclusivity of targets selected by Takeda.
In addition to the funding of the multi-target research collaboration, Takeda will invest €4.6 million in convertible debt through its venture arm, Takeda Ventures, Inc. (“TVI”), to support Egle’s corporate growth and internal programs on IL-2-based Treg modulation. Egle’s flagship program pioneers the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
Egle Therapeutics SAS is an emerging biotechnology company spun out of Institut Curie and focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases.
Takeda Pharmaceutical is a Japanese multinational pharmaceutical and biopharmaceutical company. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology.
McDermott’s team advising Egle Therapeutics was led by partner Emmanuelle Trombe (Picture) and comprised counsel Anne-France Moreau and associate Mathilde Peschard, all in Paris.
Law Firms: McDermott Will & Emery;
Clients: Egle Therapeutics;